Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar;9(3):263-272.
doi: 10.1016/S2468-1253(23)00284-4.

Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America

Affiliations
Review

Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America

Domingo Balderramo et al. Lancet Gastroenterol Hepatol. 2024 Mar.

Abstract

The incidence and prevalence of inflammatory bowel disease (IBD), namely Crohn's disease and ulcerative colitis, have increased in Latin America over the past few decades. Although incidence is accelerating in some countries in the region, other areas in Latin America are already transitioning into the next epidemiological stage-ie, compounding prevalence-with a similar epidemiological profile to the western world. Consequently, more attention must be given to the diagnosis and management of IBD in Latin America. In this Review, we provide an overview of epidemiology, potential local environmental risk factors, challenges in the management of IBD, and limitations due to the heterogenity of health-care systems, both public and private, in Latin America. Unresolved issues in the region include inadequate access to diagnostic resources, biological therapies, tight disease monitoring (including treat to target therapy, surveillance and prevention of complications, drug monitoring), and specialised IBD surgery. Local guidelines are an important effort to overcome barriers in IBD management. Advancements in long-term health-care policies will be important to promote early diagnosis, access to new treatments, and improvements in research in Latin America. These improvements will not only affect overall health care but will also lead to optimal prioritisation of IBD-related costs and resources and enhance the quality of life of people with IBD in Latin America.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests DB received speaking fees from Takeda, AbbVie, and Janssen; travel support for Janssen and Ferring; and is part of advisory boards for Takeda, AbbVie, and Janssen. ABQ has received speaker fees from AbbVie, Apsen, and Janssen. PAO declares no competing interests. MCS received meeting and travel support from Janssen and Takeda. MPGV has received advisory board fees from Takeda and Janssen and travel support from Acher, Takeda, and Ferring. RP reports consulting for AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance Biopharma, UCB, and Takeda Pharmaceuticals and has received speaker fees from AbbVie, Arena Pharmaceuticals, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire, and Takeda Pharmaceuticals. SCN has received consulting and speaker fees from AbbVie, Ferring, Janssen, Menarini, and Takeda; served as a member of scientific advisory boards for AbbVie, Ferring, and Takeda; and has received research grants from AbbVie, Ferring, and Janssen. GGK has received speaking or consulting fees from AbbVie, Janssen, Pfizer, Amgen, and Takeda; has received research support from Ferring, Janssen, AbbVie, GlaxoSmithKline, Merck, and Shire; is a consultant for Gilead; and shares ownership of one patent (treatment of inflammatory diseases, autoimmune disease, and PBC; UTI Partnership, assignee; patent WO2019046959A1; PCT/CA2018/051098; Sept 7, 2018). PGK has received consulting and speaker fees from AbbVie, Janssen, Pfizer, and Takeda and has received scientific grants from Pfizer and Takeda. Editorial note: The Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.

References

Publication types

MeSH terms